AR035891A1 - Derivados de sulfonamida, un proceso para su produccion, su uso para la fabricacion de un medicamento para el tratamiento o la prevencion de una enfermedad o condicion en donde tenga un papel o este implicada de activacion del receptor de bradiquinina beta1, y composiciones farmaceuticas y combinaci - Google Patents
Derivados de sulfonamida, un proceso para su produccion, su uso para la fabricacion de un medicamento para el tratamiento o la prevencion de una enfermedad o condicion en donde tenga un papel o este implicada de activacion del receptor de bradiquinina beta1, y composiciones farmaceuticas y combinaciInfo
- Publication number
- AR035891A1 AR035891A1 ARP020101737A ARP020101737A AR035891A1 AR 035891 A1 AR035891 A1 AR 035891A1 AR P020101737 A ARP020101737 A AR P020101737A AR P020101737 A ARP020101737 A AR P020101737A AR 035891 A1 AR035891 A1 AR 035891A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- beta1
- sulfonamide
- prevention
- role
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 230000004913 activation Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 150000003456 sulfonamides Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- -1 1,2-dichlorophenyl Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000001506 1,2,3-triazol-5-yl group Chemical group [H]N1N=NC([H])=C1[*] 0.000 abstract 1
- 125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 abstract 1
- 102000010183 Bradykinin receptor Human genes 0.000 abstract 1
- 108050001736 Bradykinin receptor Proteins 0.000 abstract 1
- 125000000172 C5-C10 aryl group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29082701P | 2001-05-14 | 2001-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035891A1 true AR035891A1 (es) | 2004-07-21 |
Family
ID=23117717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101737A AR035891A1 (es) | 2001-05-14 | 2002-05-13 | Derivados de sulfonamida, un proceso para su produccion, su uso para la fabricacion de un medicamento para el tratamiento o la prevencion de una enfermedad o condicion en donde tenga un papel o este implicada de activacion del receptor de bradiquinina beta1, y composiciones farmaceuticas y combinaci |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7109203B2 (enExample) |
| EP (1) | EP1389183B1 (enExample) |
| JP (1) | JP4150597B2 (enExample) |
| CN (1) | CN1268610C (enExample) |
| AR (1) | AR035891A1 (enExample) |
| AT (1) | ATE459598T1 (enExample) |
| BR (1) | BR0209386A (enExample) |
| CA (1) | CA2443721A1 (enExample) |
| DE (1) | DE60235536D1 (enExample) |
| ES (1) | ES2340664T3 (enExample) |
| PE (1) | PE20021158A1 (enExample) |
| PT (1) | PT1389183E (enExample) |
| WO (1) | WO2002092556A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| CA2671940A1 (en) | 2000-02-23 | 2001-08-30 | Cv Therapeutics, Inc. | Identification of partial agonists of the a2a adenosine receptor |
| WO2004011010A1 (en) * | 2002-07-29 | 2004-02-05 | Cv Therapeutics, Inc. | Myocardial perfusion imaging using a2a receptor agonists |
| US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
| US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
| CA2509881A1 (en) * | 2002-12-19 | 2004-07-08 | Elan Pharmaceuticals, Inc. | Substituted n-phenyl sulfonamide bradykinin antagonists |
| EP1802317A2 (en) * | 2004-10-20 | 2007-07-04 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| CA2640089C (en) | 2006-02-03 | 2013-07-23 | Cv Therapeutics, Inc. | Process for preparing an a2a-adenosine receptor agonist and its polymorphs |
| CA2655310A1 (en) * | 2006-06-22 | 2008-05-29 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists in the treatment of ischemia |
| US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| MX2009002299A (es) * | 2006-09-01 | 2009-03-20 | Cv Therapeutics Inc | Metodos y composiciones para incrementar la tolerancia del paciente durante metodos de formacion de imagenes del miocardio. |
| WO2008042796A2 (en) * | 2006-09-29 | 2008-04-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
| EP2099360A2 (en) * | 2007-01-03 | 2009-09-16 | CV Therapeutics Inc. | Myocardial perfusion imaging |
| ES2524259T3 (es) * | 2008-03-24 | 2014-12-04 | Novartis Ag | Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida |
| KR20110063556A (ko) * | 2008-09-29 | 2011-06-10 | 길리애드 사이언시즈, 인코포레이티드 | 다검출 전산화 단층 촬영법에 사용하기 위한 ａ-２-알파 수용체 길항제와 속도 조절제의 조합물 |
| EP2316820A1 (en) | 2009-10-28 | 2011-05-04 | Dompe S.p.A. | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| WO2013164790A1 (en) | 2012-05-03 | 2013-11-07 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| PT2813502T (pt) | 2013-06-14 | 2017-04-06 | Dompé Farm S P A | Antagonistas do recetor da bradicinina e composições farmacêuticas que os contêm |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE120047C (enExample) * | ||||
| FR2743562B1 (fr) * | 1996-01-11 | 1998-04-03 | Sanofi Sa | Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant |
| WO2001024786A1 (en) * | 1999-05-13 | 2001-04-12 | Shionogi & Co., Ltd. | Preventive or therapeutic drugs for diabetes |
| GB9913079D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
-
2002
- 2002-05-13 EP EP02742997A patent/EP1389183B1/en not_active Expired - Lifetime
- 2002-05-13 DE DE60235536T patent/DE60235536D1/de not_active Expired - Fee Related
- 2002-05-13 ES ES02742997T patent/ES2340664T3/es not_active Expired - Lifetime
- 2002-05-13 WO PCT/EP2002/005240 patent/WO2002092556A1/en not_active Ceased
- 2002-05-13 PT PT02742997T patent/PT1389183E/pt unknown
- 2002-05-13 AT AT02742997T patent/ATE459598T1/de not_active IP Right Cessation
- 2002-05-13 CA CA002443721A patent/CA2443721A1/en not_active Abandoned
- 2002-05-13 CN CNB028098900A patent/CN1268610C/zh not_active Expired - Fee Related
- 2002-05-13 BR BR0209386-3A patent/BR0209386A/pt not_active IP Right Cessation
- 2002-05-13 AR ARP020101737A patent/AR035891A1/es unknown
- 2002-05-13 JP JP2002589442A patent/JP4150597B2/ja not_active Expired - Fee Related
- 2002-05-13 US US10/475,420 patent/US7109203B2/en not_active Expired - Fee Related
- 2002-05-14 PE PE2002000401A patent/PE20021158A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE459598T1 (de) | 2010-03-15 |
| JP2004528385A (ja) | 2004-09-16 |
| CN1268610C (zh) | 2006-08-09 |
| US20040127533A1 (en) | 2004-07-01 |
| DE60235536D1 (de) | 2010-04-15 |
| EP1389183B1 (en) | 2010-03-03 |
| WO2002092556A1 (en) | 2002-11-21 |
| PE20021158A1 (es) | 2003-03-03 |
| JP4150597B2 (ja) | 2008-09-17 |
| CN1509269A (zh) | 2004-06-30 |
| US7109203B2 (en) | 2006-09-19 |
| EP1389183A1 (en) | 2004-02-18 |
| BR0209386A (pt) | 2004-07-06 |
| CA2443721A1 (en) | 2002-11-21 |
| ES2340664T3 (es) | 2010-06-08 |
| PT1389183E (pt) | 2010-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107956T1 (el) | Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον | |
| MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
| CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
| NO20012975L (no) | Nye bifenyl og bifenylanaloge forbindelser som integrinantagonister | |
| HRP20050432A2 (en) | Novel medicaments for the treatment of chronic obstructive pulmonary diseases | |
| CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
| EA200401613A1 (ru) | Лекарственное средство для лечения рака | |
| CY1108267T1 (el) | Ενωσεις που επηρεαζουν τη γλυκοκιναση | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| NO20074657L (no) | Nitrogenholdige aromatiske ringforbindelser | |
| TW200602338A (en) | Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions | |
| HUP0300567A2 (hu) | Eljárás új piperazinszármazékok elżállítására | |
| CY1110863T1 (el) | Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| BR0013311A (pt) | Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor | |
| EA200800285A1 (ru) | Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk | |
| BR0311984A (pt) | Difenilazetidinonas substituìdas cationicamente, processo para a sua preparação, medicamentos contendo estes compostos e sua aplicação | |
| ATE400270T1 (de) | Pharmazeutische zusammensetzungen mit sertaconazol für vaginale verwendung | |
| BR0304213A (pt) | Processo para a sìntese industrial de ranelato de estrÈncio e os seus hidratos | |
| MX2007011695A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
| EA200600061A1 (ru) | Бензамиды 4-(аминометил) пиперидина как 5нт-антагонисты | |
| DE602004029355D1 (de) | Sulfopyrrolderivate | |
| HUP9901376A2 (hu) | 1-Metil-karbapenem-származékok, alkalmazásuk, előállításuk, ezeket tartalmazó gyógyszerkészítmények | |
| AR041481A1 (es) | Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar | |
| NO20060718L (no) | Substituerte tiofoner og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |